Related content

Inflammatory lipids as a target for therapy in the rheumatic diseases

By McMahon Maureen   Brahn Ernest  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 8, 2008-08 ,pp. : 1213-1224

Informa Healthcare

Access to resources Recommend Favorite

The Evolving Therapy of Rheumatic Diseases, The Future is Now

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 2, Iss. 1, 2002-04 ,pp. : 1-11

Bentham Science Publishers

Access to resources Recommend Favorite

Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

By  

Arthritis & Rheumatism, Vol. 62, Iss. 12, 2010-12 ,pp. : 3569-3573

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 373-381

Bentham Science Publishers

Access to resources Recommend Favorite

Engineering high avidity CTLA4Ig for therapy of rheumatic diseases

By  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 9, 2002-09 ,pp. : 1455-1457

Informa Healthcare

Access to resources Recommend Favorite